Our History
Research & Development
Press Kit Job Listings
For Sales Professionals Benzac® Capex®
Cetaphil®
Clindagel®
Clobex®
Desowen®
Differin®
Epiduo™
Metrogel®
Oracea®
Rosanil®
Tri-Luma®
Vectical™
Acne
Dermatitis
Melasma
Psoriasis
Rosacea

About Galderma

Since the creation of Galderma in 1981 as a joint venture between Nestlé and L'Oréal, all of our resources have been channelled in a single direction: to provide innovative therapeutic, corrective and aesthetic solutions that meet the needs of dermatology patients and physicians.

Our experience has taught us that the effects of skin conditions reach much deeper than the skin itself. By treating these conditions, we help people improve the quality of their life. We pay special attention not only to the safety and efficacy of our products, but also to the way they can be best administrated by the patients themselves or by medical professionals. This constant search for the best therapeutic and aesthetic results drives our scientists to explore new areas in dermatological innovation.

Our growing international portfolio includes treatment for major skin conditions – acne, pigmentary disorders, rosacea, psoriasis / SRD (Steroid-Responsive Dermatoses).

Our History

1961	Creation of the Owen dermatology company in Dallas, Texas, USA.
1972	Acquisition of Owen by ophthalmology specialist Alcon, headquartered in Fort Worth, Texas.
1977	Nestlé acquires Alcon to strengthen its presence in the North American market.
1979	L'Oréal creates its International Dermatology Research Center (CIRD) in Sophia-Antipolis, France, specializing in fundamental research into skin physiology.
1981	Nestlé and L'Oréal form a joint venture to become the world’s leading dermatology player. Galderma is born.
1986	Galderma’s first affiliate opens for business in France, followed by a second in Italy. The International Dermatology Research Center focuses its efforts on prescription dermatology products.
1988	Galderma progressively takes over Alcon’s dermatology business, allowing it to focus exclusively on ophthalmology.
1989	Global organization implemented and new affiliates opened in Canada, Germany, Spain and the United Kingdom.
1993	Acquisition of MetroGel®/Rozex® to include rosacea treatments in the product portfolio.
1994	Galderma inaugurates its wholly-owned production plant in Alby-sur-Chéran, near Annecy in the French Alps.
1995	Launch of anti-acne treatment Differin® 0.1%, Galderma’s first home-grown dermatology product.
1996	Acquisition of a plant belonging to Wyeth-Ayerts in Montreal, Canada, to develop a state-of-the-art manufacturing plant.
1997	Acquisition of Basotherm, a subsidiary of Boehringer.
1998	Inauguration of a new R&D facility in Princeton, New Jersey, USA. Acquisition in Brazil of Darrow’s dermatology portfolio.
1999	Acquisition of Loceryl® (fungal nail infections), developed by Laboratoires Roche, together with the Scandinavian dermatology portfolio developed by Nycomed.
2000	The Montreal production unit comes on stream. Launch of Silkis® (psoriasis) in Europe and acquisition of Capex® Shampoo (seborrheic dermatitis).
2001	Licensing agreement in Europe for Metvix® (precancerous skin lesions and skin cancer treatment). Launch of Clindagel® (anti-acne).
2002	Foundation stone laid for the new Research & Development Center in Sophia-Antipolis, France. Licensing agreements for Tri-Luma® (melasma or mask of pregnancy) and Pekiron® (Loceryl® Cream) in Japan. First FDA approvals for pharmaceutical production in Montreal.
2003	Launch of Metvix® in Germany and the UK and Clobex® Lotion (inflammatory skin conditions) in the US.
2004	Opening of a new production site in Hortolandia, Brazil. Clobex® Shampoo launch in the United-States and acquisition of Tri-Luma® cream.
2005	Metrogel® 1% (rosacea) launch in the United-States. Galderma ranks Number One in D class in its markets (source: IMS Health, IMS dataview - D class - MAT Q3 2005 - 33 countries).
2006	Clobex® Spray launch in the US. Opening of the new R&D center in Sophia Antipolis, France.
2007	In-licensing of Ipsen's Botulinum Toxin Type A for Europe, Argentina and Brazil. Differin® 0.3% launch. License agreements for Pliaglis® (topical anesthetic).
2008	Launch of Pliaglis®. Acquisition of CollaGenex Pharmaceuticals.

Research & Development

Galderma research and development is an international effort, with state-of-the-art facilities around the world. The primary research center is located in Europe's largest high-technology park at Sophia-Antipolis in southeast France.

Worldwide, more than 300 skilled scientists and staff are committed to R&D. Of these, 50 are dedicated exclusively to research into the discovery of new molecules. This multi-disciplinary, multi-cultural team focuses on discovery and development of new medications for dermatological disease. To date, our research is responsible for more than 1,500 patents, 120 inventions and over 600 publications.

At Galderma R&D facilities, modern drug-design tools are used with molecular, cellular and in vivo bioassay systems to identify safe and effective new therapies. Strong working relationships between our scientists and the world's leading dermatologists help research become reality.

A major breakthrough for our company was the synthesis of adapalene, the first new retinoid molecule in more than 20 years. This led to the development of our most successful drug, Differin®, which has become the leading topical retinoid for the treatment of acne vulgaris.

Galderma’s R&D effort also includes the licensing and acquisition of dermatology drugs in various stages of development.

Interested in becoming part of this team? Check out our careers section.